Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412343 | 0.87 | PIK3CD (0.40) | SIRT2IDO1PIK3CDNOS1KMT2A | |
| SCHEMBL22337665 | 0.84 | CRHBP (0.30) | CRHBPCRHR2 | |
| SCHEMBL9849288 | 0.84 | CCR1 (0.44) | KMT2A | |
| SCHEMBL30908603 | 0.79 | CCR1 (0.50) | — | |
| SCHEMBL169736 | 0.77 | ALDH1A1 (0.52) | CYP3A4TSHRKMT2ATDP1 | |
| SCHEMBL29671296 | 0.77 | ALDH1A1 (0.52) | CYP3A4TSHRKMT2ATDP1 | |
| SCHEMBL27103126 | 0.77 | KDM4E (0.41) | PIK3CD | |
| SCHEMBL28803244 | 0.76 | MAPT (0.36) | CYP3A4NOS1TDP1 | |
| SCHEMBL207461 | 0.75 | CRHBP (0.32) | CRHBPCRHR2 | |
| SCHEMBL29533844 | 0.73 | CCR1 (0.43) | CRHBPCRHR2CYP3A4TSHRSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685351-B | OLED main body material based on triptycene framework and preparation method and application thereof | 中国科学院化学研究所 | 2023-04-18 | — | — | CN | disclosed |
| CN-109666158-B | Hybrid dynamic polymer and application thereof | 厦门逍扬运动科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114685351-A | OLED main body material based on triptycene framework and preparation method and application thereof | 中国科学院化学研究所 | 2022-07-01 | — | — | CN | disclosed |
| US-10385079-B2 | Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2019-08-20 | — | — | US | disclosed |
| WO-2017076285-A1 | PREPARATION METHOD FOR TEDIZOLID, TEDIZOLID INTERMEDIATE, AND PREPARATION METHOD THEREFOR | 浙江华海药业股份有限公司 | 2017-05-11 | — | — | WO | disclosed |
| US-8129899-B1 | Azafluorene derivative and organic light-emitting device using the derivative | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20120049176-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| US-8110685-B2 | Efficient, durable electron transport layers; low driving voltage; simple, low cost production | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-7875368-B2 | benzoxazole or imidazolopyridine compounds and charge transfer compounds, interposed between a pair of electrodes, to form organic electroluminescent devices, having high emission luminance and efficiency | CANON KABUSHIKI KAISHA (JP) | 2011-01-25 | — | — | US | disclosed |
| US-7875368-B2 | benzoxazole or imidazolopyridine compounds and charge transfer compounds, interposed between a pair of electrodes, to form organic electroluminescent devices, having high emission luminance and efficiency | CANON KABUSHIKI KAISHA (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1244665-B1 | TRIAZATRINAPHTHYRINS AND THE USE THEREOF | TRINAPCO INC (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| EP-1244665-A1 | TRIAZATRINAPHTHYRINS AND THE USE THEREOF | Trinapco LLC (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020077473-A1 | TRIAZATRINAPHTHYRINS AND THE USE THEREOF | TRINAPCO, INC. | 2002-06-20 | — | — | US | disclosed |
| US-6407089-B1 | USEFUL IN EXTRACTION OF TRANSITION METALS, IN PARTICULAR IN THE EXTRACTION OF LANTHANIDES | TRINAPCO INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2001046193-A1 | TRIAZATRINAPHTHYRINS AND THE USE THEREOF | TRINAPCO LLC (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | CRHBP 3250/4885CRHR2 983/4885CYP3A4 787/4885 |
| US-10385079-B2 | Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor | CYP51A1, CYP2F1, CYP4F11 | CRHBP 4517/4885CRHR2 4070/4885CYP3A4 27/4885 |
| US-20020077473-A1 | TRIAZATRINAPHTHYRINS AND THE USE THEREOF | TRRAP, TRHR, LBR | CRHBP 549/4885CRHR2 185/4885CYP3A4 2626/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | CRHBP 3250/4885CRHR2 983/4885CYP3A4 787/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | CRHBP 3250/4885CRHR2 983/4885CYP3A4 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.